Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

Special Report

NeurologyLive Peer Exchange

Medcast

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Videos

The neurosurgeon at Northwestern Medicine discussed diagnostic approaches, evolving treatment strategies, and the importance of timely referral in managing peripheral nerve injuries. [WATCH TIME: 3 minutes]

Emerging Considerations in Peripheral Nerve Injury and Surgical Intervention: Kevin Swong, MD

Articles

The trial of the H₃ inverse agonist aims to evalute its ability to reduce cataplexy and improve symptoms in patients with narcolepsy type 1.

Phase 2 Study to Test Therapeutic Potential of Samelisant for Narcolepsy Type 1

New 5-year findings from the National RLS Opioid Registry presented at SLEEP 2025 highlight the long-term stability and dose trends of low-dose opioid therapy in patients with restless legs syndrome.

National RLS Registry Provides Long-Term Insights Into Opioid Use for Restless Legs Syndrome

Members from Nuvig Therapeutics discussed how NVG-2089 could improve the CIDP treatment landscape by offering IVIG-like efficacy with a better safety and administration profile. [WATCH TIME: 3 minutes]

Rationale Behind NVG-2089 as New Therapy for CIDP: Pamela Conley; Alan Glicklich, MD

Marco Meglio, Assistant Managing Editor for 

, has been with the team since October 2019. Follow him on Twitter 

The neuroscientist and physician at Mount Sinai explored the role of sleep-dependent brain clearance in Alzheimer disease and how emerging research is challenging longstanding assumptions.

NeuroVoices: Andrew Varga, MD, on Debating Whether Brain Cleansing Prevents Alzheimer Disease

Senior Director, Patient Management, Care and Rehabilitation Research, National MS Society

The associate vice president of research at the National MS Society discussed a growing research initiative focused on defining and promoting evidence-based psychosocial wellness strategies for individuals with MS. [WATCH TIME: 6 minutes]

Expanding the Scope of Wellness Research in Multiple Sclerosis: Kathy Zackowski, PhD, OTR

Founder and Executive Director, Sumaira Foundation

The executive director of The Sumaira Foundation discussed a newly funded international trial assessing both approved and off-label NMOSD therapies to better inform treatment decisions and patient care. [WATCH TIME: 2 minutes]

Investigating Treatment Differences of Off-Label and Marketed Therapies for NMOSD: Sumaira Ahmed

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

CMSC 2025

PNS 2025

SLEEP 2025

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

News Network

1rem

View

Managing Neurofibromatosis Type 1 Related Plexiform Neurofibroma in Patients of Different Ages

An in-depth view into treatment and management of type 1 related plexiform neurofibroma across varying patient age ranges is provided by Kaleb Yohay, MD, of NYU Langone Health.

Kaleb Yohay, MD, introduces an upcoming Insights series dissecting care for a range of patient ages diagnosed with neurofibromatosis type 1 related plexiform neurofibroma.

UPCOMING SERIES: Managing Neurofibromatosis Type 1 Related Plexiform Neurofibroma in Patients of Different Ages

A key opinion leader offers a comprehensive overview of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN), detailing its symptoms, clinical manifestations, prevalence, and impact on patients' quality of life.

Treatment Options and Management of Neurofibromatosis Type 1 Related Plexiform Neurofibroma

A neurofibromatosis specialist explores the complexities encountered in managing NF1-PN, highlighting the distinct challenges that arise when treating patients across different age groups.

Challenges When Managing Neurofibromatosis Type 1 Related Plexiform Neurofibroma

An expert in NF1-PN describes their approach to treatment decision-making for adolescents versus adults, and identifies key barriers and unmet needs in the transition from adolescent to adult care for patients with this condition.

Transition of Care for Neurofibromatosis Type 1 Related Plexiform Neurofibroma from Adolescent to Adulthood 

A healthcare expert examines Mirdametinib as an investigational treatment for NF1-PN, focusing on its potential role in managing the condition in adolescents and adults who have moved beyond pediatric care.

Current and Emerging Treatment Options for Neurofibromatosis Type 1 Related Plexiform Neurofibroma

Kaleb Yohay, MD, an expert in NF1-PN, emphasizes the importance of multidisciplinary and comprehensive team care in managing the condition, detailing the essential team members required to facilitate a successful transition from adolescent to adult care.

Importance of Multidisciplinary Care in Management of Neurofibromatosis Type 1 Related Plexiform Neurofibroma 

Lasso - DMD Peers and Perspectives NSP-21-NRD0157

 video series brings together pairs of expert clinicians and physicians to independently provide their insights on the latest and most up-to-date clinical care for specific neurologic diseases and disorders.

EP: 1.UPCOMING SERIES: Managing Neurofibromatosis Type 1 Related Plexiform Neurofibroma in Patients of Different Ages

EP: 2.Treatment Options and Management of Neurofibromatosis Type 1 Related Plexiform Neurofibroma

EP: 3.Challenges When Managing Neurofibromatosis Type 1 Related Plexiform Neurofibroma

EP: 4.Transition of Care for Neurofibromatosis Type 1 Related Plexiform Neurofibroma from Adolescent to Adulthood

EP: 5.Current and Emerging Treatment Options for Neurofibromatosis Type 1 Related Plexiform Neurofibroma

EP: 6.Importance of Multidisciplinary Care in Management of Neurofibromatosis Type 1 Related Plexiform Neurofibroma